tetano
Editor, Senior Moderator
Blood Adv
. 2021 Nov 8;bloodadvances.2021005616.
doi: 10.1182/bloodadvances.2021005616. Online ahead of print.
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca[SUP] 1 [/SUP], Jon Salmanton-García[SUP] 2 [/SUP], Paolo Corradini[SUP] 3 [/SUP], Francesco Marchesi[SUP] 4 [/SUP], Alba Cabirta[SUP] 5 [/SUP], Roberta Di Blasi[SUP] 6 [/SUP], Remy Dulery[SUP] 7 [/SUP], Sylvain Lamure[SUP] 8 [/SUP], Francesca Farina[SUP] 9 [/SUP], Barbora Weinbergerová[SUP] 10 [/SUP], Josip Batinić[SUP] 11 [/SUP], Anna Nordlander[SUP] 12 [/SUP], Alberto Lopez-Garcia[SUP] 13 [/SUP], Lubos Drgona[SUP] 14 [/SUP], Ildefonso Espigado[SUP] 15 [/SUP], Iker Falces-Romero[SUP] 16 [/SUP], Ramon Garcia-Sanz[SUP] 17 [/SUP], Carolina Garcia-Vidal[SUP] 18 [/SUP], Anna Guidetti[SUP] 19 [/SUP], Nina Khanna[SUP] 20 [/SUP], Austin Kulesekararaj[SUP] 21 [/SUP], Johan Maertens[SUP] 22 [/SUP], Martin Hoenigl[SUP] 23 [/SUP], Nikolai Klimko[SUP] 24 [/SUP], Philipp Koehler[SUP] 25 [/SUP], Antonio Pagliuca[SUP] 26 [/SUP], Francesco Passamonti[SUP] 27 [/SUP], Oliver Cornely[SUP] 28 [/SUP], Livio Pagano[SUP] 29 [/SUP]
Affiliations
Abstract
Patients receiving chimeric antigen receptor T cells (CAR-T cells) therapy may be particularly susceptible to coronavirus disease 2019 (COVID-19) because of several factors including the immunosuppression associated to the underlying disease and delayed cytopenias. Regrettably, data on outcomes of CAR-T recipients with COVID-19 are extremely scarce. The aim of this study was to investigate the characteristics and outcomes of COVID-19 in patients treated with CAR-T therapy. The European Hematology Association - Scientific Working Group Infection in Hematology endorsed a survey to collect and analyze data from patients developing COVID-19 after CAR-T therapy. Overall, 459 patients treated with CAR-T cells were reported from 18 European centers. The prevalence of COVID-19 cases was 4.8%. Median time from CAR-T therapy and COVID-19 diagnosis was 169 days. Severe infection occurred in 66.7% of patients and 43.3% of the subjects required admission to ICU. The COVID-19 mortality was 33%. In multivariable analysis, the disease status at the time of COVID-19 trended marginally towards adverse outcome (P=0.075). In conclusion, we documented a high fatality rate for CAR-T patients with COVID-19, supporting the need to design successful interventions to mitigate the risk of infection in this vulnerable group of patients.
. 2021 Nov 8;bloodadvances.2021005616.
doi: 10.1182/bloodadvances.2021005616. Online ahead of print.
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca[SUP] 1 [/SUP], Jon Salmanton-García[SUP] 2 [/SUP], Paolo Corradini[SUP] 3 [/SUP], Francesco Marchesi[SUP] 4 [/SUP], Alba Cabirta[SUP] 5 [/SUP], Roberta Di Blasi[SUP] 6 [/SUP], Remy Dulery[SUP] 7 [/SUP], Sylvain Lamure[SUP] 8 [/SUP], Francesca Farina[SUP] 9 [/SUP], Barbora Weinbergerová[SUP] 10 [/SUP], Josip Batinić[SUP] 11 [/SUP], Anna Nordlander[SUP] 12 [/SUP], Alberto Lopez-Garcia[SUP] 13 [/SUP], Lubos Drgona[SUP] 14 [/SUP], Ildefonso Espigado[SUP] 15 [/SUP], Iker Falces-Romero[SUP] 16 [/SUP], Ramon Garcia-Sanz[SUP] 17 [/SUP], Carolina Garcia-Vidal[SUP] 18 [/SUP], Anna Guidetti[SUP] 19 [/SUP], Nina Khanna[SUP] 20 [/SUP], Austin Kulesekararaj[SUP] 21 [/SUP], Johan Maertens[SUP] 22 [/SUP], Martin Hoenigl[SUP] 23 [/SUP], Nikolai Klimko[SUP] 24 [/SUP], Philipp Koehler[SUP] 25 [/SUP], Antonio Pagliuca[SUP] 26 [/SUP], Francesco Passamonti[SUP] 27 [/SUP], Oliver Cornely[SUP] 28 [/SUP], Livio Pagano[SUP] 29 [/SUP]
Affiliations
- PMID: 34749396
- DOI: 10.1182/bloodadvances.2021005616
Abstract
Patients receiving chimeric antigen receptor T cells (CAR-T cells) therapy may be particularly susceptible to coronavirus disease 2019 (COVID-19) because of several factors including the immunosuppression associated to the underlying disease and delayed cytopenias. Regrettably, data on outcomes of CAR-T recipients with COVID-19 are extremely scarce. The aim of this study was to investigate the characteristics and outcomes of COVID-19 in patients treated with CAR-T therapy. The European Hematology Association - Scientific Working Group Infection in Hematology endorsed a survey to collect and analyze data from patients developing COVID-19 after CAR-T therapy. Overall, 459 patients treated with CAR-T cells were reported from 18 European centers. The prevalence of COVID-19 cases was 4.8%. Median time from CAR-T therapy and COVID-19 diagnosis was 169 days. Severe infection occurred in 66.7% of patients and 43.3% of the subjects required admission to ICU. The COVID-19 mortality was 33%. In multivariable analysis, the disease status at the time of COVID-19 trended marginally towards adverse outcome (P=0.075). In conclusion, we documented a high fatality rate for CAR-T patients with COVID-19, supporting the need to design successful interventions to mitigate the risk of infection in this vulnerable group of patients.